Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Advanced or metastatic malignant disease originating from solid tumors~* Adequate recovery from previous therapy or intervention; at least 21 days since major surgery or prior radiation therapy~* Measurable or evaluable disease~Exclusion criteria:~* Women of childbearing potential (WOCBP) who are breastfeeding, pregnant, or unwilling or unable to use acceptable contraception during the study and for at least 12 weeks after the last on-study dose of cetuximab~* Men unwilling to use acceptable contraception during the study if engaged in sexual relations with a WOCBP~* Symptomatic brain metastasis~* History of myocardial infarction 6 months or less prior to study entry, of severe congestive heart failure, of uncontrolled angina, or of uncontrolled arrhythmias~* Clinically relevant abnormality on screening electrocardiogram (ECG), preventing an accurate measurement of the QT interval~* Congenital long QT syndrome~* History of risk factors for ventricular tachycardia or Torsades de pointes or history of fainting, unexplained loss of consciousness, or convulsions~* Prolonged QTc interval on screening ECG (greater than 470 msec) using Fridericia's correction formula~* Heart rate slower than 50 bpm or faster than 100 bpm at rest during screening ECG measurements~* Implantable pacemaker or automatic implantable cardioverter defibrillator~* Sustained supine systolic blood pressure higher than 150 mmHg or lower than 90 mmHg or a diastolic blood pressure lower than 45 mmHg or higher than 95 mmHg at screening~* Known history of arterial thrombotic events within 6 months prior to study initiation~* Known history of significant peripheral artery disease~* Current participation in a clinical trial with another investigational new drug or device~* Receipt of an investigational new drug or device within 21 days prior to enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).